SHORT OLIGONUCLEOTIDES FOR THE INHIBITION OF VEGF EXPRESSION

Number of patents in Portfolio can not be more than 2000

United States of America Patent

APP PUB NO 20010021772A1
SERIAL NO

09365029

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

VEGF (vascular endothelial growth factor) is a key regulator of angiogenesis, and agents that selectively decrease the VEGF levels may be used to treat malignancies and other angiogenic diseases characterized by high degree of vascularization or vascular permeability. A short oligonucleotide, or a derivative thereof, which has a sequence that corresponds to a particular part of a nucleic acid sequence which encodes VEGF, and which has a maximum length of 15 nucleotides, selectively inhibits VEGF expression. The invention further relates to a method of making the oligonucleotide and the use thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
AVENTIS PHARMA DEUTSCHLAND GMBHBRUNINGSTRASSE 50 FRANKFURT AM MAIN D-65929

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
BITONTI, ALAN J RINGOES, NJ 63 1803
PEYMAN, ANUSCHIRWAN KELKHEIM, DE 48 770
UHLMANN, EUGEN GLASHUETTEN, DE 106 2598
WOESSNER, RICHARD D LEBANON, NJ 4 33

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation